Naslov
Antithrombotic therapy after intracerebral hemorrhage: a challenging decision.

Autori
Budinčević, Hrvoje ; Črnac Žuna, Petra ; Csiba, Laszlo

Vrsta, podvrsta i kategorija rada
Poglavlja u knjigama, znanstveni

Knjiga
Healthy Lifestyle and Prevention of Stroke and Other Brain Impairments

Urednik/ci
Demarin, Vida ; Đerke, Filip

Izdavač
Hrvatska akademija znanosti i umjetnosti (HAZU)

Grad
Dubrovnik

Godina
2019

Raspon stranica
50-60

ISBN
978-953-347-271-3

Ključne riječi
Antithrombotic therapy, ischemic stroke, intracerebral hemorrhage, dilemmas.

Sažetak
While oral antithrombotic (antiplatelet or anticoagulant) therapy is commonly used and recommended for prevention of vascular events such as ischemic stroke, anticoagulant therapy is essential for cardioembolic stroke prevention. The risk of ischemic stroke after intracerebral hemorrhage is 1.1-3.0% per year. Patients who suffered recent cerebral ischemia with history of previous intracerebral hemorrhage with higher risk of thromboembolism (cerebral infarction) should receive anticoagulant therapy. Patients with lower risk of thromboembolism (especially if they have amyloid angiopathy or if they are in poor overall condition) should receive antiplatelet therapy. Clopidogrel has the smallest risk of bleeding in secondary stroke prevention trials and may be warranted for patients with previous intracerebral hemorrhage. Dual antiplatelet therapy carries a higher (risk of intracerebral hemorrhage and should be avoided. Our decision regarding the use of anticoagulant therapy after ischemic stroke with history of previous intracerebral hemorrhage should be individually based and balanced between risks of thromboembolism and bleeding.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA